You have free access to this content

Cancer

Cover image for Vol. 120 Issue 7

1 April 2014

Volume 120, Issue 7

Pages 929–1085

  1. Issue information

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Issue information (pages i–ix)

      Article first published online: 29 JUL 2015 | DOI: 10.1002/cncr.29593

  2. CancerScope

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  3. Editorials

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Genetic predisposition to breast cancer: The next chapters (pages 932–934)

      Jeff Boyd

      Article first published online: 10 JAN 2014 | DOI: 10.1002/cncr.28503

      In the study by Fernandes et al in this issue, the largest cohort of patients with breast cancer studied to date was examined for mutations in the PALB gene, including all 13 coding exons and intron/exon junctions, using traditional Sanger sequencing. Future advances in our ability to develop primary and secondary approaches to breast cancer prevention will depend on new tools to test for polygenic determinants of breast cancer risk.

    2. You have free access to this content
      Obesity-associated gastrointestinal tract cancer: From beginning to end (pages 935–939)

      Nathan A. Berger

      Article first published online: 21 JAN 2014 | DOI: 10.1002/cncr.28534

      Unique aspects of the newly reported association between obesity and oral squamous cell carcinoma of the tongue are addressed in view of the current obesity pandemic and its relation to an increased risk of cancer incidence and worse cancer prognosis. Attention is called to problems evaluating and treating cancer in the presence of obesity. Potential biologic links are discussed, including: 1) increased sex steroid hormones; 2) increased growth factors; 3) altered adipokine levels; 4) low-grade inflammation; and 5) altered microbiomes. Concern is raised regarding the potential interaction between human papillomavirus and obesity, each of which is now associated with an increased relative risk of cancer of the tongue.

    3. You have free access to this content
      Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials? (pages 940–941)

      Dolores Grosso and Mark A. Weiss

      Article first published online: 31 DEC 2013 | DOI: 10.1002/cncr.28514

      For over 2 decades, a series of clinical trials has tested the efficacy of interleukin-2 as postremission therapy for patients with acute myeloid leukemia. In this issue, Kolitz et al describe a large clinical trial testing this hypothesis that ultimately failed to answer the question because of patients failing to complete the prescribed therapy.

  4. Review Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Stereotactic body radiotherapy: A critical review for nonradiation oncologists (pages 942–954)

      John P. Kirkpatrick, Christopher R. Kelsey, Manisha Palta, Alvin R. Cabrera, Joseph K. Salama, Pretesh Patel, Bradford A. Perez, Jason Lee and Fang-Fang Yin

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28515

      Stereotactic body radiotherapy (SBRT) accurately treats extracranial tumors with a few high doses of ionizing radiation, maximizing local control and minimizing damage to surrounding normal tissue. This review presents the rationale, technology, and workflow for SBRT, as well as the evidence for treatment of primary and metastatic lesions of the lung, liver, spine, and other sites.

    2. You have free access to this content
      Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia (pages 955–962)

      Joshua Yew-Suang Lim, Smita Bhatia, Leslie L. Robison and Jun J. Yang

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28531

  5. Original Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer (pages 963–967)

      Priscilla H. Fernandes, Jennifer Saam, Jenny Peterson, Elisha Hughes, Rajesh Kaldate, Shelly Cummings, Aaron Theisen, Sonia Chen, Jeffrey Trost and Benjamin B. Roa

      Article first published online: 10 JAN 2014 | DOI: 10.1002/cncr.28504

      Mutations in PALB2 (partner and localizer of BRCA2) were identified in ∼1% of samples from patients with breast cancer who were negative for BRCA1/2 deleterious mutations in the largest cohort to date. This prevalence rate is similar to CHEK2 and ATM mutation rates and suggests that PALB2 mutations explain a subset of patients with familial breast cancer.

    2. Genitourinary Disease
      You have free access to this content
      Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment (pages 968–975)

      Sushil Badrising, Vincent van der Noort, Inge M. van Oort, H. Pieter van den Berg, Maartje Los, Paul Hamberg, Jules L. Coenen, Alfons J. M. van den Eertwegh, Igle J. de Jong, Emile D. Kerver, Harm van Tinteren and Andries M. Bergman

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28518

      Enzalutamide has modest clinical activity in patients with metastatic, castration-resistant prostate cancer who received previous treatment with docetaxel and abiraterone. Prostate-specific antigen response to docetaxel and abiraterone does not predict for prostate-specific antigen response to enzalutamide.

    3. You have free access to this content
      An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer (pages 976–982)

      Walter M. Stadler, David J. Vaughn, Guru Sonpavde, Nicholas J. Vogelzang, Scott T. Tagawa, Daniel P. Petrylak, Peter Rosen, Chia-Chi Lin, John Mahoney, Sanjiv Modi, Peter Lee, Marc S. Ernstoff, Wu-Chou Su, Alexander Spira, Korinna Pilz, Richard Vinisko, Charles Schloss, Holger Fritsch, Charles Zhao and Michael A. Carducci

      Article first published online: 11 DEC 2013 | DOI: 10.1002/cncr.28519

      In this open-label, single-arm, phase 2 trial of volasertib as a second-line treatment in patients with advanced or metastatic urothelial cancer, responses are achieved with a manageable safety profile. However, there is insufficient activity for further clinical investigation of volasertib as a single agent in this setting.

    4. Head and Neck Disease
      You have free access to this content
      Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue (pages 983–991)

      Neil M. Iyengar, Amit Kochhar, Patrick G. Morris, Luc G. Morris, Xi K. Zhou, Ronald A. Ghossein, Alejandro Pino, Matthew G. Fury, David G. Pfister, Snehal G. Patel, Jay O. Boyle, Clifford A. Hudis and Andrew J. Dannenberg

      Article first published online: 21 JAN 2014 | DOI: 10.1002/cncr.28532

      In patients with early tumor stage squamous cell carcinoma of the oral tongue, obesity was an independent predictor of worse disease-specific survival in this retrospective study. This novel prognostic association may not have previously been recognized due to several confounding factors including prediagnosis weight loss.

    5. You have free access to this content
      Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma (pages 992–1001)

      Manchao Zhang, Bhavna Kumar, Longzhu Piao, Xiujie Xie, Alessandra Schmitt, Nicole Arradaza, Michael Cippola, Matthew Old, Amit Agrawal, Enver Ozer, David E. Schuller, Theodoros N. Teknos and Quintin Pan

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28538

      The intrinsic cancer stem cell pool is elevated in human papillomavirus 16 (HPV16)-positive head and neck squamous cell carcinoma in part through inactivation of p53. Patients with HPV16-positive head and neck squamous cell carcinoma respond more favorably to conventional treatment and have better outcomes, suggesting that reliance on cancer stem cell number may be insufficient to accurately assess the potential of a particular tumor for disease recurrence and/or progression.

    6. Hematologic Malignancies
      You have free access to this content
      Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement (pages 1002–1009)

      Simona Soverini, Caterina De Benedittis, Cristina Papayannidis, Stefania Paolini, Claudia Venturi, Ilaria Iacobucci, Mario Luppi, Paola Bresciani, Marzia Salvucci, Domenico Russo, Simona Sica, Ester Orlandi, Tamara Intermesoli, Antonella Gozzini, Massimiliano Bonifacio, Gian Matteo Rigolin, Fabrizio Pane, Michele Baccarani, Michele Cavo and Giovanni Martinelli

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28522

      Second-generation tyrosine kinase inhibitors ensure a more rapid debulking of the leukemic clone and have much fewer insensitive mutations than imatinib. However, long-term disease control of Philadelphia chromosome–positive acute lymphoblastic leukemias remains a problem, and the T315I mutation has become more frequent.

    7. Discipline

      Clinical Trials
      You have free access to this content
      Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (pages 1010–1017)

      Jonathan E. Kolitz, Stephen L. George, Don M. Benson Jr, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hars, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson and For the Alliance for Clinical Trials in Oncology

      Article first published online: 31 DEC 2013 | DOI: 10.1002/cncr.28516

      To the authors' knowledge, the current study is the first phase 3 trial of the subcutaneous administration of recombinant interleukin-2 in patients aged < 60 years with acute myeloid leukemia in first complete remission. Although statistical endpoints were not met, important information regarding the use of recombinant interleukin-2 in this setting as well as considerations that may affect the conduct of large phase 3 trials of this nature are presented.

    8. Disparities Research
      You have free access to this content
      Racial variation in the quality of surgical care for bladder cancer (pages 1018–1025)

      Daniel A. Barocas, JoAnn Alvarez, Tatsuki Koyama, Christopher B. Anderson, Darryl T. Gray, Jay H. Fowke, Chaochen You, Sam S. Chang, Michael S. Cookson, Joseph A. Smith Jr. and David F. Penson

      Article first published online: 11 DEC 2013 | DOI: 10.1002/cncr.28520

      An all-payer administrative data set from 3 states is used to measure racial variation in the quality of surgical care among patients undergoing bladder removal for bladder cancer. The results indicate that black patients experience a lower quality of care compared with white patients, even when they are treated by high-volume surgeons at high-volume hospitals.

    9. Epidemiology
      You have free access to this content
      Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years (pages 1026–1034)

      Masaaki Kawai, Kathleen E. Malone, Mei-Tzu C. Tang and Christopher I. Li

      Article first published online: 10 FEB 2014 | DOI: 10.1002/cncr.28402

      Young women who are current/recent smokers with high pack-year histories may have an increased risk of estrogen receptor (ER)-positive breast cancer, but not for triple-negative (negative for ER, progesterone receptor, and human epidermal growth factor receptor 2) breast cancer. An increased risk of ER-positive breast cancer may be another health risk incurred by young women who smoke.

    10. Outcomes Research
      You have full text access to this OnlineOpen article
      The influence of complications on the costs of complex cancer surgery (pages 1035–1041)

      Marah N. Short, Thomas A. Aloia and Vivian Ho

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28527

      Hospital and inpatient physician claims for the years 2005 through 2009 are analyzed for 6 cancer resections. The higher costs associated with the Agency for Healthcare Research and Quality's Patient Safety Indicators suggest that substantial savings could be achieved by targeting these indicators for quality improvement.

    11. You have free access to this content
      Cost-effectiveness of a standard intervention versus a navigated intervention on colorectal cancer screening use in primary care (pages 1042–1049)

      David R. Lairson, Melissa DiCarlo, Ashish A. Deshmuk, Heather B. Fagan, Randa Sifri, Nora Katurakes, James Cocroft, Jocelyn Sendecki, Heidi Swan, Sally W. Vernon and Ronald E. Myers

      Article first published online: 16 JAN 2014 | DOI: 10.1002/cncr.28535

      Mailed stool blood testing significantly boosts colorectal cancer screening use, and the intervention is well within the cost range of other practice-based studies of colorectal cancer screening promotion. However, the tailored navigation intervention is more effective than the standard intervention, and the gains come at substantially higher costs.

    12. You have free access to this content
      National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010 (pages 1050–1058)

      Yun Wang, Deborah Schrag, Gabriel A. Brooks and Francesca Dominici

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28537

      For Medicare fee-for-service beneficiaries, initial pancreatic cancer hospitalization, surgical resection, and rehospitalization rates increased over the last decade, but 1-year mortality rates declined.

    13. You have free access to this content
      Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma (pages 1059–1067)

      Richard W. Joseph, Payal Kapur, Daniel J. Serie, Jeanette E. Eckel-Passow, Mansi Parasramka, Thai Ho, John C. Cheville, Eugene Frenkel, Dinesh Rakheja, James Brugarolas and Alexander Parker

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28521

      BAP1 (BRCA1 associated protein-1) is mutated in ∼10% of clear cell renal cell carcinomas (ccRCC), and BAP1 mutations lead to decreased expression of the protein. This study demonstrates that loss of BAP1 protein is independently associated with decreased survival in patients with low-risk ccRCC.

      Corrected by:

      Erratum: Erratum: Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma

      Vol. 120, Issue 11, 1752–1753, Article first published online: 22 FEB 2014

    14. Pediatric Oncology
      You have free access to this content
      Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers (pages 1068–1075)

      Simone Hettmer, Natasha M. Archer, Gino R. Somers, Ana Novokmet, Amy J. Wagers, Lisa Diller, Carlos Rodriguez-Galindo, Lisa A. Teot and David Malkin

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28507

      Children with germline TP53 mutations are predisposed to develop anaplastic rhabdomyosarcoma at a young age. Extension of the current Chompret criteria for Li-Fraumeni syndrome to include children with anaplastic rhabdomyosarcoma irrespective of family history should be considered.

    15. Radiation Oncology
      You have full text access to this OnlineOpen article
      Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer (pages 1076–1082)

      Bradford S. Hoppe, Jeff M. Michalski, Nancy P. Mendenhall, Christopher G. Morris, Randal H. Henderson, Romaine C. Nichols, William M. Mendenhall, Christopher R. Williams, Meredith M. Regan, Jonathan J. Chipman, Catrina M. Crociani, Howard M. Sandler, Martin G. Sanda and Daniel A. Hamstra

      Article first published online: 30 DEC 2013 | DOI: 10.1002/cncr.28536

      No differences in quality-of-life summary scores are observed between an intensity-modulated radiotherapy cohort and a proton therapy cohort during early follow-up (up to 2 years). Responses to individual questions suggest possible differences in specific bowel symptoms between the 2 cohorts.

  6. Correspondence

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content

SEARCH

SEARCH BY CITATION